SOUTHWEST ONCOLOGY GROUP STUDIES

描述：堪萨斯大学参与了SWOG研究 从1973年开始 自1993年以来，主要研究者一直是Sarah博士 泰勒是一位热情而富有成效的临床研究者。 二十 临床研究者参加了在华盛顿大学进行的SWOG研究， 堪萨斯，利用大学医疗中心和附近的弗吉尼亚州 医院 这个研究小组的目标是参与设计 并在恶性疾病方面开展多学科临床试验， 研究这些疾病的生物学方面， 调查生活质量、护理费用和长期 治疗并发症，开发新的方法，如远程医疗， 增加参与癌症研究的患者人数并改善随访 预防试验，并为SWOG的全面领导做出贡献。 堪萨斯大学SWOG研究的参与者包括专家 从内科肿瘤学，血液学，外科，泌尿学，放射肿瘤学， 妇科肿瘤学和病理学。 Giri博士是院长的主席 和颈部放射治疗小组委员会，Kimler博士是该小组委员会的主席。 临床前治疗研讨会和联合主席的发展 治疗委员会。 堪萨斯调查人员已经协调了六名 多学科方案（四个II期和两个III期组间方案 协议）。 此外，堪萨斯调查人员还协调了其他18名 第二或第三阶段方案和八项组间研究。 SWOG参与者 来自堪萨斯的是14篇手稿和5篇摘要的主要作者， 30篇手稿和12篇摘要的共同作者。 堪萨斯大学及其10个附属机构登记了115名患者， 1995年的SWOG研究和1996年的91例患者。 1996年，堪萨斯是 第17届世界杯足球赛 目前，有587名患者存活， 在SWOG研究中被跟踪，在SWOG机构中排名第十。

Description: The University of Kansas has participated in SWOG studies since 1973. The Principal Investigator since 1993 has been Dr. Sarah Taylor, an enthusiastic and productive clinical investigator. Twenty clinical investigators participate in SWOG studies at the University of Kansas, utilizing both the University Medical Center and the nearby VA Hospital. The goals of this research group are to participate in the design and conduct of multidisciplinary clinical trials in malignant diseases, to investigate biological aspects of these diseases within the group, to investigate issues of quality of life, cost of care and long-term complications of treatment, to develop new methods such as telemedicine to increase patient accrual and improve follow-up, to participate in cancer prevention trials, and to contribute to the overall leadership of the SWOG. Participants in SWOG studies at the University of Kansas include specialists from medical oncology, hematology, surgery, urology, radiation oncology, gynecological oncology, and pathology. Dr. Giri is the chair of the Head and Neck Radiation Therapy Subcommittee, and Dr. Kimler is the chair of the Pre-Clinical Therapeutics Workshop and co-chair of the Developmental Therapeutics Committee. Kansas investigators have coordinated six multidisciplinary protocols (four phase II and two phase III intergroup protocols). In addition, Kansas investigators have coordinated 18 other phase II or III protocols and eight intergroup studies. SWOG participants from Kansas were the primary authors of 14 manuscripts and 5 abstracts and co-authors of 30 manuscripts and 12 abstracts. The University of Kansas and its 10 affiliates registered 115 patients to SWOG studies in 1995 and 91 patients in 1996. In 1996, Kansas was the seventeenth leading accruer in SWOG. Currently, 587 patients are alive and being followed on SWOG studies, ranking tenth among SWOG institutions.